August 12, 2026

Product Labels Miss Hidden Chemicals

Testing found that nearly 60% of top-rated "Go" products failed contamination testing.

MDSpire News

August 07, 2026

Surgical Site May Raise Infection Risk After Firearm Injury

A nationwide cohort linked selected surgical procedures to higher odds of bacterial infection following firearm injury, while infection was not independently associated with mortality among those who survived 1 night of hospitalization.

MDSpire News

August 06, 2026

Povorcitinib in Phase 3 Hidradenitis Suppurativa Trials

Both oral doses met the primary endpoint at week 12, with long‐term efficacy summarized descriptively through week 54.

MDSpire News

August 04, 2026

Distribution Barriers May Reduce Biologic Drug Survival

A real‐world Brazilian registry suggests that challenges in biologic distribution were associated with treatment interruption, particularly among therapies requiring more frequent dosing.

MDSpire News

July 30, 2026

Daily Itch Duration Linked to Quality-of-Life Burden

Daily itch duration emerged as the strongest factor linking disease severity with quality of life, ahead of sleep disturbance, scratching frequency, and average itch intensity.

MDSpire News

July 29, 2026

Medical Oddities: Tattoo Regret Meets Nanotech

This week is about smart tattoos, social clues, pool perks, and tea's surprising brain connection.

MDSpire News

July 23, 2026

GRAPPA, EULAR Criteria May Identify Complex PsA

Application of newly proposed GRAPPA and EULAR criteria in a longitudinal cohort identified progressively smaller groups of patients with early psoriatic arthritis who experienced persistently worse patient-reported outcomes.

MDSpire News

July 22, 2026

Ixekizumab May Improve Early Response After Secukinumab Failure

A real-world cohort found faster early skin responses with ixekizumab than with guselkumab or ustekinumab following secukinumab treatment failure, while all three biologics demonstrated favorable safety.

MDSpire News

July 22, 2026

Medical Oddities: When AI Meets the Afterlife

Ghosts, germs, B cells, and brews—this week's research is anything but ordinary.

MDSpire News

July 22, 2026

Early Research Examines Daraxonrasib in NRAS-Mutant Melanoma

Preclinical research showed antiproliferative activity against NRAS-mutant melanoma cell lines and antitumor activity against preclinical melanoma models.

The ASCO Post